Skip to content
Storytelling Co – Lifestyle
Author:
Annovis Bio Inc.
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
September 23, 2026
Annovis to Host Corporate Update Webinar on September 2, 2026
August 25, 2026
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
August 14, 2026
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
July 7, 2026
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
July 1, 2026
Annovis Bio Regains NYSE Listing Compliance
May 26, 2026
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
May 20, 2026
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
May 19, 2026
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
May 15, 2026
Annovis CEO to Present on Multi-Protein Model of Alzheimer’s Disease at Fierce Biotech Week 2026
May 7, 2026
1
2
Next Page
→